A few days ago we had access to this alert in Medscape. An MS patient, that had completed the 6-hour vigilance period after the first dose of fingolimod, died unexpectedly the next day. We don’t know much about it and we should wait until this case is resolved and an official report released. We only […]
Two weeks ago the annual meeting of the ECTRIMS was held in Amsterdam. As usual, several interesting presentations, some of them probably good enough to change the immediate future of MS clinical practice, were presented. Among them, new data regarding the next 3 new oral therapies that probably will be approved when their results are […]